Literature DB >> 28052852

High-Dose Ampicillin-Sulbactam Combinations Combat Polymyxin-Resistant Acinetobacter baumannii in a Hollow-Fiber Infection Model.

Justin R Lenhard1,2,3, Nicholas M Smith1,2, Zackery P Bulman1,2, Xun Tao4, Visanu Thamlikitkul5, Beom S Shin6, Roger L Nation7, Jian Li7, Jürgen B Bulitta4, Brian T Tsuji8,2.   

Abstract

Acinetobacter baumannii is emerging with resistance to polymyxins. In 24-h time-kill experiments, high-dose ampicillin-sulbactam in combination with meropenem and polymyxin B achieved additivity or synergy against 108 CFU/ml of two clinical A. baumannii isolates resistant to all three drugs (maximum reductions, 1.6 and 3.1 logs). In a 14-day hollow-fiber infection model, high-dose ampicillin-sulbactam (8/4 g every 8 h, respectively) in combination with meropenem (2 g every 8 h) and polymyxin B (1.43 mg/kg of body weight every 12 h with loading dose) resulted in rapid (96 h) eradication of A. baumannii.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Acinetobacter; antibiotic resistance; antimicrobial combinations; meropenem; polymyxins; sulbactam; synergism

Mesh：

Substances：

Year:  2017        PMID： 28052852      PMCID： PMC5328540          DOI： 10.1128/AAC.01268-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  19 in total

1.  Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens.

Authors:  Ana M Sandri; Cornelia B Landersdorfer; Jovan Jacob; Márcio M Boniatti; Micheline G Dalarosa; Diego R Falci; Tainá F Behle; Rosaura C Bordinhão; Jiping Wang; Alan Forrest; Roger L Nation; Jian Li; Alexandre P Zavascki
Journal:  Clin Infect Dis       Date:  2013-05-22       Impact factor: 9.079

2.  High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumannii.

Authors:  Justin R Lenhard; Jürgen B Bulitta; Terry D Connell; Natalie King-Lyons; Cornelia B Landersdorfer; Soon-Ee Cheah; Visanu Thamlikitkul; Beom Soo Shin; Gauri Rao; Patricia N Holden; Thomas J Walsh; Alan Forrest; Roger L Nation; Jian Li; Brian T Tsuji
Journal:  J Antimicrob Chemother       Date:  2016-09-15       Impact factor: 5.790

3.  Detection of pan drug-resistant Acinetobacter baumannii in Germany.

Authors:  Stephan Göttig; Teresa M Gruber; Paul G Higgins; Maik Wachsmuth; Harald Seifert; Volkhard A J Kempf
Journal:  J Antimicrob Chemother       Date:  2014-05-15       Impact factor: 5.790

Review 4.  Agents of Last Resort: Polymyxin Resistance.

Authors:  Keith S Kaye; Jason M Pogue; Thien B Tran; Roger L Nation; Jian Li
Journal:  Infect Dis Clin North Am       Date:  2016-06       Impact factor: 5.982

5.  Pan-resistant Acinetobacter baumannii mediastinitis treated successfully with tigecycline: a case report.

Authors:  Ayşe Yasemin Tezer Tekçe; Ayşe Erbay; Hatice Çabadak; Serap Yağcı; Nihal Karabiber; Süha Şen
Journal:  Surg Infect (Larchmt)       Date:  2011-02-24       Impact factor: 2.150

6.  Pharmacokinetic/pharmacodynamic evaluation of sulbactam against Acinetobacter baumannii in in vitro and murine thigh and lung infection models.

Authors:  Yuta Yokoyama; Kazuaki Matsumoto; Kazuro Ikawa; Erika Watanabe; Akari Shigemi; Yasuhiro Umezaki; Koyo Nakamura; Keiichiro Ueno; Norifumi Morikawa; Yasuo Takeda
Journal:  Int J Antimicrob Agents       Date:  2014-03-30       Impact factor: 5.283

Review 7.  Acinetobacter baumannii: emergence of a successful pathogen.

Authors:  Anton Y Peleg; Harald Seifert; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

Review 8.  Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems.

Authors:  Oren Zusman; Tomer Avni; Leonard Leibovici; Amos Adler; Lena Friberg; Theodouli Stergiopoulou; Yehuda Carmeli; Mical Paul
Journal:  Antimicrob Agents Chemother       Date:  2013-08-05       Impact factor: 5.191

9.  High-dose ampicillin-sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumannii.

Authors:  Alex P Betrosian; Frantzeska Frantzeskaki; Anna Xanthaki; George Georgiadis
Journal:  Scand J Infect Dis       Date:  2007

10.  Development and validation of a liquid chromatography-mass spectrometry assay for polymyxin B in bacterial growth media.

Authors:  Soon-Ee Cheah; Jurgen B Bulitta; Jian Li; Roger L Nation
Journal:  J Pharm Biomed Anal       Date:  2014-01-24       Impact factor: 3.935
View more
  22 in total

1.  Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling.

Authors:  Rajbharan Yadav; Kate E Rogers; Phillip J Bergen; Jürgen B Bulitta; Carl M J Kirkpatrick; Steven C Wallis; David L Paterson; Roger L Nation; Jeffrey Lipman; Jason A Roberts; Cornelia B Landersdorfer
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

2.  Minocycline Alone and in Combination with Polymyxin B, Meropenem, and Sulbactam against Carbapenem-Susceptible and -Resistant Acinetobacter baumannii in an In Vitro Pharmacodynamic Model.

Authors:  Maya Beganovic; Kathryn E Daffinee; Megan K Luther; Kerry L LaPlante
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

Review 3.  Multidrug Resistant Acinetobacter baumannii: Resistance by Any Other Name Would Still be Hard to Treat.

Authors:  David A Butler; Mark Biagi; Xing Tan; Samah Qasmieh; Zackery P Bulman; Eric Wenzler
Journal:  Curr Infect Dis Rep       Date:  2019-11-16       Impact factor: 3.725

Review 4.  In search for a synergistic combination against pandrug-resistant A. baumannii; methodological considerations.

Authors:  Stamatis Karakonstantis; Petros Ioannou; Diamantis D Kofteridis
Journal:  Infection       Date:  2022-01-04       Impact factor: 3.553

5.  Using machine learning to optimize antibiotic combinations: dosing strategies for meropenem and polymyxin B against carbapenem-resistant Acinetobacter baumannii.

Authors:  N M Smith; J R Lenhard; K R Boissonneault; C B Landersdorfer; J B Bulitta; P N Holden; A Forrest; R L Nation; J Li; B T Tsuji
Journal:  Clin Microbiol Infect       Date:  2020-02-12       Impact factor: 8.067

Review 6.  Rescuing the Last-Line Polymyxins: Achievements and Challenges.

Authors:  Sue C Nang; Mohammad A K Azad; Tony Velkov; Qi Tony Zhou; Jian Li
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

7.  Meropenem Combined with Ciprofloxacin Combats Hypermutable Pseudomonas aeruginosa from Respiratory Infections of Cystic Fibrosis Patients.

Authors:  Vanessa E Rees; Rajbharan Yadav; Kate E Rogers; Jürgen B Bulitta; Veronika Wirth; Antonio Oliver; John D Boyce; Anton Y Peleg; Roger L Nation; Cornelia B Landersdorfer
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

Review 8.  New Perspectives on Antimicrobial Agents: Cefiderocol.

Authors:  Erin K McCreary; Emily L Heil; Pranita D Tamma
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191

9.  Application of a Physiologically Based Pharmacokinetic Model to Develop a Veterinary Amorphous Enrofloxacin Solid Dispersion.

Authors:  Kaixiang Zhou; Meixia Huo; Wenjin Ma; Kun Mi; Xiangyue Xu; Samah Attia Algharib; Shuyu Xie; Lingli Huang
Journal:  Pharmaceutics       Date:  2021-04-22       Impact factor: 6.321

Review 10.  Losing the Battle but Winning the War: Can Defeated Antibacterials Form Alliances to Combat Drug-Resistant Pathogens?

Authors:  Song Oh; Raymond Chau; Anh T Nguyen; Justin R Lenhard
Journal:  Antibiotics (Basel)       Date:  2021-05-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.